Chemioterapia nel sarcoma di Kaposi mediterraneo: 20 anni di esperienza

Translated title of the contribution: Chemotherapy of mediterranean Kaposi's sarcoma in the elderly: 20 years' experience

L. Brambilla, R. Labianca, S. Fossati, S. Ferrucci, M. Taglioni, V. Boneschi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.

Original languageItalian
Pages (from-to)433-437
Number of pages5
JournalGiornale Italiano di Dermatologia e Venereologia
Volume135
Issue number4
Publication statusPublished - 2000

Fingerprint

Kaposi's Sarcoma
gemcitabine
Drug Therapy
Vinblastine
Etoposide
Pharmaceutical Preparations
Italy
Therapeutics
Referral and Consultation

ASJC Scopus subject areas

  • Dermatology

Cite this

Chemioterapia nel sarcoma di Kaposi mediterraneo : 20 anni di esperienza. / Brambilla, L.; Labianca, R.; Fossati, S.; Ferrucci, S.; Taglioni, M.; Boneschi, V.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 135, No. 4, 2000, p. 433-437.

Research output: Contribution to journalArticle

Brambilla, L. ; Labianca, R. ; Fossati, S. ; Ferrucci, S. ; Taglioni, M. ; Boneschi, V. / Chemioterapia nel sarcoma di Kaposi mediterraneo : 20 anni di esperienza. In: Giornale Italiano di Dermatologia e Venereologia. 2000 ; Vol. 135, No. 4. pp. 433-437.
@article{5621a030e1584296884bda533ec5001a,
title = "Chemioterapia nel sarcoma di Kaposi mediterraneo: 20 anni di esperienza",
abstract = "Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80{\%}), whereas in the second line it was 50{\%} for drugs used in the second line apart from gemcitabine which has given 100{\%} response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.",
keywords = "Aged, Antineoplastic agents, Combined, Drug therapy, Kaposi, Sarcoma, Therapeutic use",
author = "L. Brambilla and R. Labianca and S. Fossati and S. Ferrucci and M. Taglioni and V. Boneschi",
year = "2000",
language = "Italian",
volume = "135",
pages = "433--437",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Chemioterapia nel sarcoma di Kaposi mediterraneo

T2 - 20 anni di esperienza

AU - Brambilla, L.

AU - Labianca, R.

AU - Fossati, S.

AU - Ferrucci, S.

AU - Taglioni, M.

AU - Boneschi, V.

PY - 2000

Y1 - 2000

N2 - Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.

AB - Background. When classical Kaposi's sarcoma (CKS) shows an aggressive behaviour, the use of systemic chemotherapy is indicated. Several drugs are active in this disease, but the role of single agents, both in the first and second line, is not yet clear. The 20 years experience of a referral group in Italy is reported here. Methods. One hundred and twenty patients were treated with seven drugs in monochemotherapy: vinblastine, vinorelbine and oral etoposide in the first line and vinblastine, i.v. etoposide, gemcitabine and i.m. bleomycin in the second line. Objective responses and toxicity were evaluated according to WHO criteria. Results. In the first line, the activity of therapy was similar (CR+ PR: 60-80%), whereas in the second line it was 50% for drugs used in the second line apart from gemcitabine which has given 100% response. Toxicity was limited and acceptable for each treatment. Personal experience confirms the usefulness of treating patients affected by aggressive CKS with systemic chemotherapy, in order to obtain control of the disease and to reduce the related symptoms. Conclusions. The evaluation of the role of a drug in comparison to another one requires the implementation of a large comparative trials, in order to establish a 'standard' systemic treatment for this disease.

KW - Aged

KW - Antineoplastic agents

KW - Combined

KW - Drug therapy

KW - Kaposi

KW - Sarcoma

KW - Therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=0033800374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033800374&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033800374

VL - 135

SP - 433

EP - 437

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 4

ER -